Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 9, 2006
app pub date -
Jun 10, 2005
filing date -
Jun 11, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with Erbitux.TM.(cetuximab). Viral and non-viral gene delivery systems are disclosed.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully